Floatz logo

Tetrahydrouridine

Neoplasm

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

928 Active assets in the Neoplasm cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
VITAMIN D
Tanta University
Phase 4BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Bxcl501
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

Tetrahydrouridine is also rated in:

urinary bladder neoplasmDormant
B
Indicative ·
59 / 100
View asset →
head and neck neoplasmDormant
B
Indicative ·
58 / 100
View asset →
lung neoplasmDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →